Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1266-5511 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases.
Participants will be asked to give information about their health. Partipants will continue normal way of life and will not get any medication other than those prescribed to them by the doctor.
The study will last for about 6 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with Type 2 Diabetes (T2D) | Selected for inclusion in the study by their primary or secondary care physicians |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician. |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope | Percentage patients | At the time of patient enrolment (Day 1) |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of T2D patients with high risk of Atherosclerotic cardiovascular disease (ASCVD) and without eASCVD | Percentage patients | At the time of patient enrolment (Day 1) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Type 2 Diabetes (T2D) patients seen in routine visits
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency (dept. 2834) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Manama | Bahrain | ||||
| Novo Nordisk Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36775980 | Background | Verma S, Sabbour H, Alamuddin N, Alawadi F, Alkandari H, Almahmeed W, Assaad-Khalil SH, Haddad J, Lombard L, Malik RA, Mashaki Ceyhan E, Prasad P, Tombak G, Salek S. A cross-sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa (PACT-MEA): Study design and rationale. Diabetes Obes Metab. 2023 Jun;25(6):1444-1452. doi: 10.1111/dom.15011. Epub 2023 Mar 3. | |
| 40994644 |
Not provided
Not provided
"According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Alexandria |
| Egypt |
| Novo Nordisk Investigational Site | Amman | Jordan |
| Novo Nordisk Investigational Site | As Sālimīyah | Kuwait |
| Novo Nordisk Investigational Site | Doha | Qatar |
| Novo Nordisk Investigational Site | Johannesburg | South Africa |
| Novo Nordisk Investigational Site | Abu Dhabi | United Arab Emirates |
| Derived |
| Salek S, Sabbour H, Alamuddin N, Alawadi F, Alkandari H, Almahmeed W, Assaad-Khalil SH, Ceyhan EM, Haddad J, Lombard L, Ngome M, Malik RA, Yadav G. Physician self-reported factors driving clinical decision-making in management of patients with T2D and ASCVD/high risk of ASCVD across the middle East and Africa: a cross-sectional study. Front Pharmacol. 2025 Sep 9;16:1558515. doi: 10.3389/fphar.2025.1558515. eCollection 2025. |
| 40754331 | Derived | Assaad-Khalil SH, Bassyouni A, Toaima D, Gawish HS, El Hefnawy H, Megallaa M, Abushady M, ElKafrawy N, Hosny SS, Massoud TM. Prevalence and risk factors of atherosclerotic cardiovascular disease in Egyptians with type 2 diabetes: findings from the PACT-MEA study and call for action. BMJ Open. 2025 Aug 3;15(8):e092861. doi: 10.1136/bmjopen-2024-092861. |
| 40106223 | Derived | Haddad JA, Annabi FOA, Abbasi H, AlSamen MAA, Ammari FL, Haddad FH, Haddad SE, Jaradat M, Khassawneh A, Khatib N, Magableh A, Al-Mousa E. The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes in Jordan: The PACT-MEA Study. Diabetes Ther. 2025 May;16(5):899-913. doi: 10.1007/s13300-025-01718-7. Epub 2025 Mar 19. |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided